'Nvp' presentation slideshows

Prevention of Mother-to-Child HIV Transmission: State of the Art

Prevention of Mother-to-Child HIV Transmission: State of the Art. Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and Human Development National Institutes of Health Department of Health and Human Services. Overview.

712 views • 70 slides

Suvaporn Anugulruengkitt , Piyarat Suntarattiwong , Pradthana Ounchanum ,

Safety and nevirapine concentrations of 6-week triple antiretroviral prophylaxis in high risk HIV-exposed infants. Suvaporn Anugulruengkitt , Piyarat Suntarattiwong , Pradthana Ounchanum , Ussanee Srirompotong , Watsamon Jantarabenjakul , Jiratchaya Sophonphan ,

367 views • 26 slides

DART

Discordance between virological/immunological and clinical outcomes at 48 weeks, in a randomised comparison of ZDV/3TC/NVP and ZDV/3TC/ABC in patients with low CD4 counts in Africa.

379 views • 19 slides

Mashi Study

254 views • 17 slides

HIVNET 023

HIVNET 023. A Phase I/II Study of the Safety and Pharmacokinetics of Nevirapine Given Daily, Twice a Week or Weekly As Prophylaxis in Breastfeeding Infants From Birth to 24 Weeks in Durban, South Africa and Harare, Zimbabwe. Hoosen M. Coovadia, University of Natal, Durban, South Africa

299 views • 14 slides

Comparison of NNRTI vs PI/r

104 views • 10 slides

Comparison of NNRTI vs PI/r

Comparison of NNRTI vs PI/r. EFV vs LPV/r vs EFV + LPV/r ACTG A5142 EFV vs LPV/r Mexican Study NVP vs ATV/r ARTEN EFV vs ATV/r ACTG A5202. ARTEN Study: NVP vs ATV/r, in combination with TDF/FTC. Design. Randomisation * 1:1:1 Open-label. W48. W144. N = 188. > 18 years

218 views • 6 slides